Recruiting Macular Degeneration Studies in Hagerstown
Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensit...
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 int...
About Macular Degeneration Clinical Trials in Hagerstown
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 3 macular degeneration clinical trials recruiting participants in Hagerstown, MARYLAND. These studies are seeking a combined 602 participants. Research is being sponsored by 4D Molecular Therapeutics, Galimedix Therapeutics Inc, EyeBiotech Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Hagerstown — FAQ
Are there macular degeneration clinical trials in Hagerstown?
Yes, there are 3 macular degeneration clinical trials currently recruiting in Hagerstown, MARYLAND. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hagerstown?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hagerstown research site will contact you about next steps.
Are clinical trials in Hagerstown free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hagerstown studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 3 active trials in Hagerstown are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov